在哥伦比亚治疗严重喘的奥马利祖马布的成本效益
Jefferson Antonio Buendía1,2, Diana Guerrero Patiño2, Andrés Felipe Zuluaga Salazar2,3
1Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
概括
在哥伦比亚,奥马利祖马布对于严重的不受控制的喘是不具有成本效益的. 需要大幅降低83%的成本才能在这个群体中被视为具有成本效益.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 奥马利祖马布是一种向免疫球蛋白E的单克隆抗体,对治疗严重喘有经济方面的考虑.
- 无法控制的严重喘带来了重大挑战,需要评估新的治疗方案.
研究的目的:
- 估计与哥伦比亚严重失控喘成年人的标准护理相比,奥马利祖马布的成本效益.
- 为在中等收入国家背景下提供关于奥马利祖马布采用的决策提供经济证据.
主要方法:
- 一个马尔科夫状态过渡模型被用来进行终身成本效益分析.
- 整合了当地成本和国际公用事业数据,利用哥伦比亚特有的和全球数据进行概率.
主要成果:
- 奥马利祖马布的增量成本效益比率 (ICER) 估计为每QALY获得的36,846美元.
- 奥马利祖马布在每QALY的支付意愿门为5,180美元时,其具有低成本效益的可能性 (3.2%).
结论:
- 目前,奥马利祖马布不是哥伦比亚严重失控喘的具有成本效益的治疗方法.
- 为了实现成本效益,需要大幅降低 (83%) omalizumab 的价格.
- 调查结果强调了在资源有限的环境中进行经济评估的必要性,并建议在类似经济体进行进一步的研究.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
313
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
313
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
218
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
218
Asthma: Pathogenesis and Management
421
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
421
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324


